Co-treatment with imipramine averted haloperidol-instigated tardive dyskinesia: Association with serotonin in brain regions.
Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia (TD). 0.2 mg/kg/rat dosage of haloperidol provided orally to rats for 2 weeks enhanced vacuous chewing movements that escalated when the process proceeded for 5 weeks. Following 2 weeks co-injection 5 mg/kg dosage of IMI was diminished haloperidol-instigated VCMs and fully averted following five weeks. The potency of 8-OH-DPAT-instigated locomotor activity exhibited higher in saline+haloperidol treated rats while not observed in IMI+ haloperidol treated rats. 8-OH-DPAT-instigated low 5-hydroxytryptamine (5-HT; serotonin) metabolism was higher in saline+ haloperidol treated rats when compare to IMI+ haloperidol treated rats in both regions of brain (striatum and midbrain). It is recommended that IMI possibly competent in averting TD, in cases receiving treatment to antipsychotics.
Department of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Noreen
N
Samad
Department of Food and Biomedical Engineering, NED University of Engineering, Karachi, Pakistan.
Farzana
F
Yasmin
Neuroscience Research Laboratory, Dr. Panjwani Center for Molecular Medicine & Drug Research, University of Karachi, Pakistan.
Darakhshan Jabeen
DJ
Haleem
D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D006220:Haloperidol; D007099:Imipramine / Q000494:pharmacology*; D008297:Male; D008409:Mastication / Q000187:drug effects; D009043:Motor Activity / Q000187:drug effects; D017208:Rats, Wistar; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism*; D058825:Serotonin 5-HT1 Receptor Agonists; D000068760:Serotonin and Noradrenaline Reuptake Inhibitors / Q000494:pharmacology*; D000071057:Tardive Dyskinesia / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control*; D013997:Time Factors
D058825:Serotonin 5-HT1 Receptor Agonists; D000068760:Serotonin and Noradrenaline Reuptake Inhibitors; D044282:Receptor, Serotonin, 5-HT1A; D012701:Serotonin; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D006220:Haloperidol; D007099:Imipramine